Search

Displaying results 1081 - 1090 of 5261 in total
  1. Drug

    Irbesartan

    go.drugbank.com/drugs/DB01029
    ApprovedInvestigational

    Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected t...

    Mixtures: Nb-irbesartan HCT, Nb-irbesartan HCTProducts: Nb-irbesartan
  2. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. … Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

  3. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [L11575] Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. … [A190492] The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent.

  4. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … By improving the three-year survival rate from 55% to 84%,[L32288] and considering the lack of alternative therapies available, fosdenopterin appears poised to become a standard of therapy in the management

  5. Drug

    Ribostamycin

    go.drugbank.com/drugs/DB03615
    ApprovedWithdrawn

    Ribostamycin is an aminoglycoside antibiotic[A187166] isolated from _Streptomyces ribosidificus_[A187178] listed as one of the World Health Organization's critically important antimicrobials.[L9071]

  6. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). … [A252340] New thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and [reteplase], have also been developed.

  7. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic … It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding

  8. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [L10974] On December 22, 2025, the FDA expanded this indication to include pediatric patients aged 10 years and older. [L54873,L54878]

  9. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua.

  10. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … [A180478] Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.